Editor's note: Recently, Suzhou Guoke Junhao Biotechnology Co., Ltd. (referred to as "Guokejunhao") announced that it has obtained 10 million yuan from Guoqian Venture Investment Management (Suzhou) Co., Ltd. (referred to as "Guoqian Venture Capital") Pre-A round financing.
Suzhou Guoke Junhao Biological Technology Co., Ltd. was established in July 2018 and belongs to the Taiwan Junhao Group. Its core business is the development, production and sales of POCT medical devices and diagnostic reagents. The small microfluidic chemiluminescence detector developed by the company incorporates Industry 4.0 technology, combines the concept of the Internet of Things with remote customer service, and realizes intelligent diagnosis. The instrument is miniaturized and integrates the functions of a large instrument, and its detection performance is comparable to that of a large instrument, and it supports whole blood on the machine and the operation is faster. The core technology of the instrument-the microfluidic chip has an excellent production process and a very low cost. With the ability and resources of Junhao Group in the field of intelligent manufacturing of precision instruments, the company can quickly achieve mass production.
Company Chairman: Ye Shengfa
Ye Shengfa, Chairman of Guoke Junhao, said that since its establishment, Guoke Junhao has been focusing on the field of chemiluminescence immunoassay. The small-scale fully automated microfluidic chemiluminescence detection system successfully developed combines high-end microfluidic chips with magnetic particle chemiluminescence. The technology POCT platform is combined to complete the inspection quickly and efficiently. At the same time, it can complete multiple biochemical index combination projects with low cost and fool operation. The products can be used in hospitals, laboratories, field emergency, ordinary families and other places. With the gradual improvement of in vitro diagnostic policies and the increase in demand in the medical market, the system has broad market prospects. The Guoke Junhao team will continue to uphold the concept of excellence, innovation and sustainability, and strive to become the benchmark of the global smart medical industry!
Company General Manager: Dr. Lin Jiahui
Dr. Lin Jiahui, general manager of Guoke Junhao, has been cultivating in disc microfluidic chip technology for more than ten years. She said: As an immunodiagnostic technology, chemiluminescence has become the mainstream immunodiagnostic method in China. Since the establishment of the company, the team has attached great importance to technological research and development and innovation, and has applied for 9 invention patents and 6 utility model patents. With the increasing competition at home and abroad, perfect technology and strong R & D capabilities will support the company's long-term competitiveness in this field. Guoke Junhao has a deep background and strength in intelligent manufacturing of automated precision instruments. As a professional institution engaged in equity investment in the medical device field, Guoqian Venture Capital has rich clinical and expert resources. The pace of Junhao occupying domestic and foreign markets.
Chairman of Guoqian Venture Capital: Dr. Zhang Xu
Zhang Xu, Chairman of Guoqian Venture Capital, said: Junhao Precision Industry Co., Ltd., a subsidiary of Guoke Junhao, has continuously entered the field of process equipment, automation equipment and precision mold components, and has become a leading manufacturer of electronic precision machinery equipment in Taiwan. . Based on this, combined with the solid theoretical foundation and professional technology, rich development experience and team management capabilities of the responsible person Dr. Lin Jiahui in the field of microfluidic technology, I believe that Guoke Junhao will certainly be able to achieve the goal of multi-scenario application in the near future With the positioning, the instrument + chip + reagent trinity sales model also helps it quickly occupy the market.
Guoqian Venture Capital Management (Suzhou) Co., Ltd.
Guoqian Venture Capital Management (Suzhou) Co., Ltd. was established by Dr. Zhang Xu and other six national “Thousand Talents Plan” experts in the medical device field, Suzhou Medical Institute of Chinese Academy of Sciences, Haichuang Think Tank and other shareholders, focusing on medical devices and in vitro diagnostics Venture capital institution for early stage projects in the field of reagents and biotechnology.
Based on the business philosophy of “achieving the dreams of others”, Guoqian Venture Capital seeks a high level in the process of talent project introduction, innovation and entrepreneurship project evaluation, and technological achievement transformation with the national “Thousand Talents Plan” experts and its radiating high-end technological talents as the core Quality investment target, and use the powerful think tank resources of the national "Thousand Talents Plan" experts to provide professional guidance and resource integration in technology, industry, policy, clinical, industrialization, etc. At the same time, through talent project introduction and service, entrepreneurship project innovation Incubating and accelerating, holding high-end industry forums, industrial investment and integration and other services to create an innovative technology investment and industrial integration platform with national characteristics. Strive to establish a medical device industry cluster and ecological circle in Suzhou High-tech Zone in 3-5 years and become one of the main promoters of the development of the domestic medical device industry.